Expression and function of junctional adhesion molecule-C in human and experimental arthritis by Palmer,  G. et al.
Available online http://arthritis-research.com/content/9/4/R65Open AccessVol 9 No 4Research article
Expression and function of junctional adhesion molecule-C in 
human and experimental arthritis
Gaby Palmer1*, Nathalie Busso2*, Michel Aurrand-Lions3, Dominique Talabot-Ayer1, 
Véronique Chobaz-Péclat2, Claudia Zimmerli3, Philippe Hammel3, Beat A Imhof3 and Cem Gabay1
1Division of Rheumatology, Department of Internal Medicine, University Hospital, 26 avenue Beau-Séjour, 1211 Geneva 14, Switzerland and 
Department of Pathology and Immunology, University of Geneva School of Medicine, 1 rue Michel-Servet, 1211 Geneva 4, Switzerland
2Division of Rheumatology, Department of Medicine, University Hospital, Nestlé 05-5029, 1011 Lausanne, Switzerland
3Department of Pathology and Immunology, University of Geneva School of Medicine, 1 rue Michel-Servet, 1211 Geneva 4, Switzerland
* Contributed equally
Corresponding author: Cem Gabay, cem.gabay@hcuge.ch
Received: 9 Mar 2007 Revisions requested: 11 Apr 2007 Revisions received: 11 Jun 2007 Accepted: 5 Jul 2007 Published: 5 Jul 2007
Arthritis Research & Therapy 2007, 9:R65 (doi:10.1186/ar2223)
This article is online at: http://arthritis-research.com/content/9/4/R65
© 2007 Palmer et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Junctional adhesion molecule-C (JAM-C) is an adhesion
molecule involved in transendothelial migration of leukocytes. In
this study, we examined JAM-C expression in the synovium and
investigated the role of this molecule in two experimental mouse
models of arthritis. JAM-C expression was investigated by
reverse transcriptase-polymerase chain reaction and
immunohistochemistry. The effects of a monoclonal anti-JAM-C
antibody were assessed in antigen-induced arthritis (AIA) and K/
BxN serum transfer-induced arthritis. JAM-C was expressed by
synovial fibroblasts in the lining layer and associated with
vessels in the sublining layer in human and mouse arthritic
synovial tissue. In human tissue, JAM-C expression was
increased in rheumatoid arthritis (RA) as compared to
osteoarthritis synovial samples (12.7 ± 1.3 arbitrary units in RA
versus 3.3 ± 1.1 in OA; p < 0.05). Treatment of mice with a
monoclonal anti-JAM-C antibody decreased the severity of AIA.
Neutrophil infiltration into inflamed joints was selectively
reduced as compared to T-lymphocyte and macrophage
infiltration (0.8 ± 0.3 arbitrary units in anti-JAM-C-treated versus
2.3 ± 0.6 in isotype-matched control antibody-treated mice; p <
0.05). Circulating levels of the acute-phase protein serum
amyloid A as well as antigen-specific and concanavalin A-
induced spleen T-cell responses were significantly decreased in
anti-JAM-C antibody-treated mice. In the serum transfer-induced
arthritis model, treatment with the anti-JAM-C antibody delayed
the onset of arthritis. JAM-C is highly expressed by synovial
fibroblasts in RA. Treatment of mice with an anti-JAM-C antibody
significantly reduced the severity of AIA and delayed the onset
of serum transfer-induced arthritis, suggesting a role for JAM-C
in the pathogenesis of arthritis.
Introduction
The recruitment of leukocytes to inflamed tissues is a highly
regulated multistep process, which includes leukocyte rolling
on the vascular endothelium, activation of leukocytes and sub-
sequent firm adhesion to endothelial ligands, transendothelial
migration from the vascular lumen into the surrounding tissue,
and migration of inflammatory cells through the tissue in
response to chemokine gradients [1,2]. The successive
events in this cascade are mediated by coordinated interac-
tion of adhesion molecules expressed by leukocytes, endothe-
lial cells, and the surrounding tissues. In particular, endothelial
transmigration involves the interaction of leukocytes with
adhesion molecules expressed on the endothelial cell surface,
whereas their retention likely involves interaction with adhe-
sion molecules present on different cell types residing within
the target tissue.Page 1 of 12
(page number not for citation purposes)
AIA = antigen-induced arthritis; ConA = concanavalin A; DMEM = Dulbecco's modified Eagle's medium; ELISA = enzyme-linked immunosorbent 
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endothelial adhesion molecules regulating the paracellular
trafficking, such as CD99, platelet endothelial cell adhesion
molecule-1 (PECAM-1), or the junctional adhesion molecules
(JAMs) [3-6]. The JAM protein family consists of three mem-
bers called JAM-A, JAM-B, and JAM-C, which are immu-
noglobulin (Ig) superfamily molecules with two extracellular Ig
domains and a short cytoplasmic tail, ending with a PDZ-bind-
ing motif, involved in cytoskeletal and signal transduction inter-
actions [7]. JAM-C was initially described as an adhesion
molecule localized at interendothelial contacts and as an
integrin ligand mediating interactions between vascular cells
and leukocytes [5,8]. JAM-C is also expressed in mesenchy-
mal and epithelial cells, suggesting that in addition to its role
in inflammatory cell recruitment, it might contribute to the
retention of leukocytes within inflamed tissues [9,10].
Soluble JAM-C has been demonstrated to inhibit neutrophil
transmigration both in vitro and in vivo [6]. Similarly, mono-
clonal antibodies directed against JAM-C reduced the accu-
mulation of leukocytes in alveoli during acute pulmonary
inflammation in mice [11], prevented leukocyte influx in a
murine model of allergic contact dermatitis [12], and
decreased inflammatory cell recruitment and tissue injury in
cerulein-induced acute pancreatitis [13].
Uncontrolled activation of leukocytes and endothelial cells is a
feature of pathologic chronic inflammation, such as observed
in rheumatoid arthritis (RA). The mechanisms regulating
recruitment and retention of leukocytes in the joint in experi-
mental models of inflammatory arthritis and the role of various
adhesion molecules in human RA are still poorly understood.
The aim of the present study was to investigate the role of
JAM-C in arthritis. We describe the expression of JAM-C in
human and mouse synovium and synovial fibroblasts. Further-
more, we observed that a monoclonal anti-JAM-C antibody
decreased the severity of mouse antigen-induced arthritis
(AIA) and delayed the onset of K/BxN serum transfer-induced
arthritis.
Materials and methods
Mice
Male C57BL/6 mice were obtained from Janvier (Le Genest-
St-Isle, France) and used between 9 and 11 weeks of age.
KRN T-cell receptor transgenic mice, developed in the labora-
tory of Diane Mathis and Christophe Benoist, were kindly pro-
vided by the Institut de Génétique et de Biologie Moléculaire
et Cellulaire (Strasbourg, France) [14] and were maintained
on a C57BL/6 background (K/B). Progeny bearing the Vβ6
transgenic T-cell receptor were identified by cytofluorometry
of peripheral blood lymphocytes using antibodies labeled with
anti-CD4 phycoerythrin (clone L3T4; BD Pharmingen, San
Diego, CA, USA) and anti-Vβ6 fluorescein isothiocyanate
(clone RR4-7; BD Pharmingen). NOD/Lt mice were pur-
chased from The Jackson Laboratory (Bar Harbor, ME, USA).
All mice were housed under conventional conditions, and
water and standard laboratory chow were provided ad libitum.
All animal experiments were approved by the Animal Ethics
Committee of the Geneva University School of Medicine and
by the Geneva Veterinarian Office.
Antigen-induced arthritis
Mice were injected intradermally at the base of the tail with
100 μg of methylated bovine serum albumin (mBSA) (Fluka,
part of Sigma-Aldrich, St. Louis, MO, USA), emulsified in com-
plete Freund's adjuvant (Difco Laboratories Inc., now part of
Becton Dickinson and Company, Franklin Lakes, NJ, USA)
containing 5 mg/ml Mycobacterium tuberculosis. Heat-killed
Bordetella pertussis organisms (0.2 × 109) (Berna, Bern,
Switzerland) were injected intraperitoneally as an additional
adjuvant. On day 7, a booster injection of 100 μg of mBSA in
incomplete Freund's adjuvant (Becton Dickinson and Com-
pany) was given at the base of the tail. On day 21, arthritis was
induced by intra-articular injection of 100 μg of mBSA in 10 μl
of phosphate-buffered saline (PBS) into the left knee joint of
mBSA-immunized mice, the right knee being injected with
sterile PBS alone. The monoclonal anti-JAM-C antibody H36
[15] or an isotype-matched control antibody (9B5, rat IgG2a
anti-human CD44) was injected (150 μg/mouse, intraperito-
neal [i.p.]) 1 hour before intra-articular injection of mBSA into
the left knee and of PBS into the right knee. Mice were sacri-
ficed 4 or 8 days after induction of arthritis, the latter group
receiving a second injection of antibodies on day 4. The devel-
opment of arthritis was followed by measuring technetium-
99m (Tc) uptake in the knees on days 1, 3, and 7 after intra-
articular mBSA injection as previously described [16].
K/BxN serum transfer-induced arthritis
Arthritic K/BxN mice were obtained by crossing K/B mice with
NOD/Lt (N) animals. Arthritic adult K/BxN mice were bled and
the sera were pooled. Recipient C57BL/6 mice were injected
with pooled serum (100 μl of serum i.p. on days 0 and 6). The
monoclonal anti-JAM-C antibody H36 or an isotype-matched
control antibody (9B5) was injected (150 μg/mouse, i.p.) 1
hour before the first injection of serum on day 0 and then again
on days 4 and 8. Mice were sacrificed on day 13. The devel-
opment of arthritis was assessed daily, and the severity of
arthritis was scored in a blinded fashion for each paw on a 3-
point scale, in which 0 = normal appearance, 1 = localized
edema/erythema on one digit or over one surface of the paw,
2 = edema/erythema involving more than one surface of the
paw, and 3 = marked edema/erythema involving the whole
paw. The scores of all four paws were added for a composite
score.
Histological grading of arthritis
At sacrifice, the knees (AIA) or the paws (K/BxN serum trans-
fer-induced arthritis) were dissected and fixed in 10% buffered
formalin for 7 days. Fixed tissues were decalcified for 3 weeks
in 15% EDTA (ethylenediaminetetraacetic acid), dehydrated,Page 2 of 12
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whole joint were stained with safranin O and counterstained
with fast green/iron hematoxilin. Histological sections were
graded independently by two observers unaware of the treat-
ment group by using the following parameters. For AIA, syno-
vial membrane thickness, which reflects the degree of synovial
inflammation and hyperplasia, was scored on a scale of 0 to 6
(0 = normal thickness to 6 = maximal thickness). Cartilage pro-
teoglycan depletion, reflected by loss of safranin O staining
intensity, was scored on a scale of 0 (fully stained cartilage) to
6 (totally unstained cartilage). For the K/BxN serum transfer-
induced arthritis, synovial membrane thickness around the
ankle, exudates in the ankle region, and ankle edema were
scored on a scale of 0 to 3 (0 = normal to 3 = maximal).
Human synovial tissue samples
Specimens of synovial tissue from osteoarthritis (OA) and RA
patients undergoing joint surgery of the knee or the hip were
obtained from the Department of Orthopedics of the Centre
Hospitalier Universitaire Vaudois (Lausanne, Switzerland).
Patients with RA fulfilled at least four of the seven American
College of Rheumatology revised criteria for RA. All tissues
were cut into small pieces and immediately frozen in precooled
hexane and stored at -70°C until use. All subsequent analyses
were performed on consecutive cryostat sections (one repre-
sentative piece analyzed per patient). Samples were obtained
after appropriate informed consent, and their use for research
was approved by the Ethics Committee.
Immunohistochemistry
JAM-C expression was studied by immunohistochemistry
(IHC) using rabbit polyclonal antibodies against human or
murine JAM-C on cryostat sections of human or murine syno-
vial tissues, respectively. Antibodies against mouse and
human JAM-C have been previously described [17,18]. Lym-
phocyte, macrophage, and neutrophil infiltrations into mouse
synovium were detected by IHC using anti-CD3, anti-MAC-2,
or anti-MPO antibodies, respectively, on paraffin-embedded
sections. Briefly, frozen or deparaffinized and rehydrated sec-
tions were incubated for 30 minutes at room temperature with
5% BSA and 20% normal serum. Endogenous peroxidase
activity was blocked with 3% H2O2 for 10 minutes. Slides
were then overlaid with the primary antibody for 1 hour at room
temperature. Bound antibody was visualized using the avidin-
biotin-peroxidase complex (Vectastain Elite ABC kit; Vector
Laboratories, Burlingame, CA, USA). The color was devel-
oped by 3,3'-diaminobenzidine (Sigma-Aldrich) containing
0.01% H2O2. After extensive washing in water, slides were
counterstained with Papanicolaou (Merck AG, Dietikon, Swit-
zerland) and mounted in Merckoglass (Merck AG, Dietikon,
Switzerland). Staining specificity was confirmed using preim-
mune serum (for anti-JAM-C IHC), isotype-matched antibodies
(for anti-CD3 and anti-MAC-2 IHC), or matched serum (for
anti-MPO IHC) as primary antibodies. An incubation without
the first antibody served as a negative control. Infiltration of
lymphocytes, macrophages, and neutrophils was assessed by
semi-quantitative visual scoring of CD3, MAC-2, and MPO
immunostaining in the synovial membrane. For each marker,
staining was graded independently by two observers (una-
ware of animal treatment) on a scale of 0 (no staining at all) to
3 (maximal staining). To estimate JAM-C levels in human syno-
vial tissues, sections were magnified 400 times through a
microscope (Olympus, Mont-sur-Lausanne, Switzerland),
scanned using a JVC TK-C1381 color video camera (Olym-
pus) and analyzed using Semper 6P image analysis software
(Synoptics Ltd, Cambridge, UK). The results were expressed
as the ratio between the number of pixels associated to immu-
noreactive regions and between the number of pixels of the
total area examined.
Culture of human and mouse synovial fibroblasts
Human synovial fibroblasts were isolated by collagenase
digestion as reported previously [19]. Murine synovial fibrob-
lasts were prepared from synovial tissue dissected from AIA
knee joints. The tissue was finely minced and then digested in
0.1% collagenase (Gibco-BRL, now part of Invitrogen Corpo-
ration, Carlsbad, CA, USA) in Dulbecco's modified Eagle's
medium (DMEM) for 2 hours at 37°C. Undigested material
was removed, and cells were collected by centrifugation. Both
human and murine synovial fibroblasts were kept in primary
culture, at 37°C, in a humidified atmosphere containing 5%
CO2, in DMEM supplemented with 10% fetal calf serum and
100 U/ml penicillin and 100 μg/ml streptomycin. Non-adher-
ent cells were removed by repeated washings during cell cul-
ture, and cells were used at the third passage.
Reverse transcriptase-polymerase chain reaction
Total RNA was isolated from human synovial tissue samples,
knees of mice with AIA or collagen-induced arthritis [20], paws
of mice with K/BxN serum transfer-induced arthritis, and
human and mouse synovial fibroblasts using the TRIzol rea-
gent (Invitrogen Corporation). Total RNA (1 to 3 μg) was
digested with DNAse I (Promega AG, Wallisellen, Switzer-
land) and reverse-transcribed using avian myeloblastosis virus
reverse transcriptase (RT) (Promega AG) and random hex-
amer primers. Polymerase chain reaction (PCR) amplification
(40 cycles for JAM-C and 30 cycles for β-actin) was per-
formed using Taq DNA polymerase (Qiagen AG, Hombrech-
tikon, Switzerland) and the following primers: murine Jam-C
forward primer 5'-TGC TGC TGC TCT TCA GGG GC-3' and
murine Jam-C reverse primer 5'-GAC AGG GGT CAC TGG
CTT C-3' (GenBank accession number: NM023844), human
JAM-C forward primer 5'-CTG GGG AAG ACA TCC CTG
AAG-3' and human JAM-C reverse primer 5'-AGT GCG GAT
GTA GTT AAC TCC-3' (GenBank accession number:
NM032801), and β-actin forward primer 5'-CCAAG-
GCCAACCGCGAGAAGATGAC-3' and β-actin reverse
primer 5'-AGGGTACATGGTGGTGCCGCCAGAC-3' (Gen-
Bank accession number: M10277). Annealing temperatures
were 55°C for JAM-C and 60°C for β-actin. The absence ofPage 3 of 12
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ing RNA samples, which had not been reverse-transcribed,
and distilled water was used as a negative control for PCR
amplification. The identity of the amplified products was con-
firmed by DNA sequencing.
Measurement of serum amyloid A levels
Blood was taken at the end of experiment by cardiac puncture.
Serum levels of serum amyloid A (SAA) were determined
using a direct enzyme-linked immunosorbent assay (ELISA) as
previously described [21]. The detection limit for this test is 13
μg/ml.
T-cell proliferation assay
Spleen cells were harvested on day 4 after intra-articular
mBSA injection and seeded at 4 × 105 cells per well in 96-well
plates in 200 μl of RPMI 1640 medium containing 100 IU/ml
penicillin, 100 μg/ml streptomycin, 5 × 10-5 M β-mercaptoeth-
anol, and 1% mouse serum. Cells were incubated at 37°C
with 5% CO2 for 72 hours without or with 10 μg/ml mBSA or
5 μg/ml concanavalin A (ConA) (Amersham Pharmacia Bio-
tech, now part of GE Healthcare, Little Chalfont, Buckingham-
shire, UK). During the final 18 hours of incubation, 3H-
thymidine was added at 1 μCi/well. Cells were harvested and
radioactivity was counted to determine 3H-thymidine incorpo-
ration into DNA as a measure of cell proliferation.
Determination of cytokine and antibody production
Spleen cells were harvested on day 4 after intra-articular
mBSA injection and cultured for 72 hours without or with 10
μg/ml mBSA or 5 μg/ml ConA. Culture supernatants were har-
vested, and interferon-gamma (IFN-γ) and interleukin-10 (IL-
10) levels were quantified by ELISA by means of a commercial
DuoSet ELISA Development System (R&D Systems, Abing-
don, UK) for IFN-γ and a BD OptEIA Set (BD Biosciences,
Heidelberg, Germany) for IL-10. The detection limits for both
tests are 31 pg/ml. Serum levels of total anti-mBSA antibodies
were measured as described previously [16].
Statistical analysis
Significance of differences was calculated by analysis of vari-
ance, chi-square test, or Wilcoxon rank sum test as indicated.
A difference between experimental groups was considered
significant when the p value was less than 0.05.
Results
Expression of junctional adhesion molecule-C in human 
and mouse synovial tissues
We investigated JAM-C expression in human OA and RA syn-
ovial samples by IHC using polyclonal antibodies against
human JAM-C. Interestingly, expression of JAM-C was mainly
found in the lining layer and was associated with vessels in the
sublining layer (Figure 1a,b) in OA and in RA synovial biopsies.
JAM-C expression, as quantified by histomorphometry, was
significantly higher in RA than in OA samples (Figure 1c). RT-
PCR analysis showed JAM-C mRNA expression in OA and
RA synovial biopsies as well as in purified human synovial
fibroblasts (Figure 1d), suggesting that these cells account for
at least part of the JAM-C expression observed in the lining
layer by IHC.
To confirm our findings and extend our observations to another
species, we then studied the pattern of JAM-C expression in
two different mouse models of experimental arthritis: AIA and
K/BxN serum transfer-induced arthritis (Figure 2a,b). In both
cases, IHC using polyclonal antibodies against mouse JAM-C
showed expression of JAM-C in a pattern similar to that found
in human arthritic tissues. Expression of the protein was mainly
found in the lining layer and was associated with vessels in the
sublining layer. RT-PCR analysis showed JAM-C mRNA
expression both in mouse synovial tissue samples and in cul-
tured mouse synovial fibroblasts (Figure 2c).
Antibodies against junctional adhesion molecule-C 
decrease the severity of murine antigen-induced arthritis
To investigate a potential role for JAM-C in arthritis, we tested
the effect of the monoclonal anti-JAM-C antibody H36 [17] on
the course of AIA. Injection of an isotype-matched control anti-
body did not affect the development of AIA as compared to
treatment with PBS (data not shown). In contrast, treatment of
mice with the anti-JAM-C antibody significantly decreased the
severity of arthritis, as quantified by Tc uptake on day 3 (Figure
3a). Histology showed lower inflammation in knees of mice
treated with the anti-JAM-C antibody as compared to isotype-
matched control antibody-treated mice (Figure 3b,c) on day 8,
whereas cartilage damage was similar in the two groups. The
lack of effect of JAM-C antibody on cartilage might be
accounted for, in part, by the lack of sensitivity of safranin O
staining, which cannot detect subtle changes in cartilage deg-
radation. Serum SAA levels, which reflect the systemic inflam-
matory response and are maximal on day 4, were significantly
decreased in anti-JAM-C antibody-treated mice (Figure 3d).
Antibodies against junctional adhesion molecule-C 
decrease the cellular immune response during antigen-
induced arthritis
Proliferation of spleen cells isolated from mice treated with the
isotype-matched control antibody was significantly increased
upon restimulation with mBSA or ConA in vitro (Figure 4a).
This proliferative response was significantly reduced in mice
treated with the anti-JAM-C antibody (Figure 4a). Similarly,
IFN-γ production was significantly increased by stimulation
with mBSA or ConA in cells isolated from isotype-matched
control antibody-treated mice, and this IFN-γ response was
also markedly reduced in cells of anti-JAM-C antibody-treated
mice (Figure 4b). IL-10 production was not detectable in
spleen cell supernatants. A similar, though less marked, dimi-
nution of cell proliferation and IFN-γ production was also
observed in draining lymph node cell cultures obtained from
anti-JAM-C antibody-treated mice (data not shown). LymphPage 4 of 12
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treated mice produced detectable levels of IL-10 upon stimu-
lation with mBSA, and this IL-10 production was also reduced
in cells isolated from anti-JAM-C antibody-treated mice. Total
anti-BSA IgG and anti-BSA IgG2a levels were comparable in
anti-JAM-C antibody-treated and isotype-matched control anti-
body-treated mice on days 4 and 8 (Figure 4c,d). Anti-BSA
IgG1 levels were transiently elevated at day 4, but not at day
8, in the anti JAM-C antibody-treated mice.
Neutrophil infiltration in the inflamed synovium was selectively
reduced in anti-JAM-C antibody-treated mice, whereas lym-
phocyte and macrophage infiltrations per field were similar in
anti-JAM-C antibody and isotype-matched control antibody-
treated mice (Figure 5).
Treatment with anti-junctional adhesion molecule-C 
antibody delays the onset of K/BxN serum transfer-
induced arthritis
To specifically investigate a potential role of JAM-C in the
effector phase of arthritis, we tested the impact of anti-JAM-C
antibody treatment in a model of K/BxN serum transfer-
induced arthritis. Treatment with the anti-JAM-C antibody
delayed the onset of K/BxN serum transfer-induced arthritis,
Figure 1
Expression of junctional adhesion molecule-C (JAM-C) in human arthritic synoviumt iti  i . Expression of JAM-C was examined by immunohistochemistry in 
human osteoarthritis (OA) (a) and rheumatoid arthritis (RA) (b) synovial tissue. The panels labeled 1 show the original magnification (× 100). The 
panels labeled 2 show expression of JAM-C in the synovial lining layer (magnification × 400), and panels labeled 3 show JAM-C associated with 
blood vessels in the sublining (magnification × 400). The panels labeled 4 show negative control sections incubated with preimmune serum. Scale 
bars = 60 μm (panels 1 and 4) and 15 μm (panels 2 and 3). (c) Quantification of JAM-C expression in OA and RA synovial tissues. JAM-C immuno-
histochemical synovial tissue sections from four different OA and RA patients were scanned, and the surface of immunoreactive areas was deter-
mined and expressed as the percentage of the surface of the image examined. Results are expressed as the mean ± standard error of the mean. *p 
< 0.001 OA versus RA as assessed using the Wilcoxon rank sum test. (d) Reverse transcriptase-polymerase chain reaction (PCR) analysis of JAM-
C mRNA expression in human synovial tissue samples and in cultured human synovial fibroblasts. A representative agarose gel electrophoresis of 
PCR products is shown. bp, base pairs; H2O, polymerase chain reaction negative control; hSF1 and hSF2, human rheumatoid arthritis synovial 
fibroblast cultures from two different patients used after the third passage; OA, osteoarthritis synovial tissue; RA, rheumatoid arthritis synovial tissue; 
RT neg, non-reverse-transcribed sample.Page 5 of 12
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anti-JAM-C antibody-treated mice as compared to isotype-
matched control antibody-treated mice on day 3 (Figure 6a). In
contrast, the severity of arthritis was not affected by the treat-
ment in this model (Figure 6b). We also verified that injection
of the isotype-matched control antibody 9B5 per se had no
effect on the development of serum transfer-induced arthritis
(data not shown).
Histological analysis of the paws showed no difference
between anti-JAM-C antibody-treated and control mice at day
13 (Figure 6c), although we cannot exclude the possibility that
histological differences, and in particular differences in neu-
trophil infiltration, could have been detectable at an earlier time
point. The serum SAA levels, which are not significantly
increased in this model, were not affected by treatment with
the anti-JAM-C antibody. In contrast, ConA-induced spleen
cell proliferation in vitro was decreased in anti-JAM-C anti-
body-treated arthritic mice as compared to isotype-matched
antibody-treated controls (fold increase in proliferation over
unstimulated control cultures: 11.3 ± 0.67 for anti-JAM-C anti-
body-treated mice, n = 10; 37.1 ± 4.49 for control mice, n =
10; p < 0.05).
Discussion
The protein JAM-C is an adhesion molecule involved in junc-
tional interaction between adjoining endothelial, epithelial, or
fibroblastic cells [7]. It has also been reported to regulate
monocyte and neutrophil adhesion to and transmigration
through various types of cells, including fibroblast, epithelial,
Figure 2
Expression of junctional adhesion molecule-C (JAM-C) in mouse arthritic synovium and synovial fibroblasts. Expression of JAM-C was examined by 
immunohistochemistry in knee joints of mice with antigen-induced arthritis (AIA) (a) and in paws of mice with K/BxN serum transfer-induced arthritis 
(b). The left panels show expression of JAM-C in the synovial lining layer (upper panel) and associated with blood vessels in the sublining (lower 
panel). The right panels show negative control sections incubated with preimmune serum. Original magnification × 400 (scale bar = 20 μm). (c) 
Reverse transcriptase-polymerase chain reaction (PCR) analysis of JAM-C mRNA expression in mouse synovial tissue samples and in cultured 
mouse synovial fibroblasts. A representative agarose gel electrophoresis of PCR products is shown. AIA1 and AIA2, antigen-induced arthritis syno-
vial tissue; bp, base pairs; H2O, polymerase chain reaction negative control; K/BxN1 and K/BxN2, K/BxN serum transfer-induced arthritis synovial 
tissue; mSF1 and mSF2, two different mouse synovial fibroblast cultures isolated from antigen-induced arthritis synovial tissue; RTneg, non reverse-
transcribed sample.Page 6 of 12
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Available online http://arthritis-research.com/content/9/4/R65and endothelial cells [6,11,22,23]. Although these results sug-
gest that JAM-C is involved in leukocyte recruitment during
inflammation, the role of JAM-C in human inflammatory dis-
eases has not been well studied. Here, we found that JAM-C
is present on vessels and synovial fibroblasts of human and
mouse arthritic lesions. An antibody against JAM-C inhibits the
recruitment of neutrophils to the joints during AIA and delays
the onset of serum transfer-induced arthritis. Finally, treatment
with anti-JAM-C antibody decreases the T-cell response in
AIA.
Recruitment of inflammatory cells, maintenance of the inflam-
matory state, and the sustained retention of leukocytes within
arthritic lesions are mandatory for the development of arthritis.
The invasion of leukocytes into the synovial tissue is controlled
at the molecular level by interactions between adhesion mole-
cules expressed on endothelial cells and leukocytes [24]. The
adhesion molecule JAM-C expressed by endothelial cells has
been shown to bind the leukocyte integrin Mac-1 expressed by
neutrophils and monocytes [6,8]. Although Mac-1 is not the
only leukocyte adhesion molecule involved in leukocyte migra-
tion to arthritic lesions, this integrin, together with lymphocyte
function-associated antigen-1 (LFA-1) and α4β1 integrins,
has been shown to contribute to the development of the dis-
ease [25-27]. We know from previous studies that our anti-
JAM-C monoclonal antibody does not prevent direct interac-
tion between Mac-1 and JAM-C [15]. Nevertheless, it still
blocks neutrophil recruitment to inflamed tissues [13]. One
possibility is that treatment with the anti-JAM-C antibody mod-
ulates the contribution of Mac-1 or α4β1 integrins to leukocyte
Figure 3
Treatment with anti-JAM-C antibody decreases the severity of antigen-induced arthritisi f ti -i  rt riti . (a) Joint inflammation on days 1, 3, and 7 after intra-articular 
methylated bovine serum albumin (mBSA) injection. Results are expressed as the ratio of technetium-99m (99mTc) uptake in the arthritic over the 
non-inflamed knee. The mean ± standard error of the mean (SEM) of the ratios is shown for anti-JAM-C antibody-treated (n = 10 for days 1 and 3, n 
= 6 for day 7; black symbols) and isotype-matched control antibody-treated (n = 10 for days 1 and 3, n = 5 for day 7; open symbols) mice. Joint 
inflammation was significantly reduced in anti-JAM-C antibody-treated mice on day 3. (b) Representative histological sections for anti-JAM-C anti-
body-treated (upper panel) and isotype-matched control antibody-treated (lower panel) mice 8 days after intra-articular mBSA injection (original 
magnification × 40, scale bar = 125 μm). Arrowheads: cartilage erosions; asterisks: pannus; broken lines: synovial thickness. (c) Histological scores 
shown as the mean ± SEM for anti-JAM-C antibody-treated (n = 6, black columns) and isotype-matched control antibody-treated (n = 5, open col-
umns) mice 8 days after intra-articular mBSA injection. Synovial inflammation was significantly reduced in anti-JAM-C antibody-treated mice. (d) Cir-
culating levels of serum amyloid A (SAA) on days 4 and 8 after intra-articular mBSA injection. Results shown represent the mean ± SEM for anti-
JAM-C antibody-treated (n = 5 on day 4, n = 6 on day 8, black columns) and isotype-matched control antibody-treated (n = 5 at both time points, 
open columns) mice. Serum SAA levels were significantly decreased in anti-JAM-C antibody-treated mice on day 4. *p < 0.05 versus control mice, 
as assessed by analysis of variance. Ab, antibody; JAM-C, junctional adhesion molecule-C.Page 7 of 12
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Treatment with anti-JAM-C antibody decreases the T-cell responseti  r  the T-cel  response. (a) Proliferation of spleen cells isolated from anti-JAM-C antibody-treated (n = 5) 
and isotype-matched control antibody-treated (n = 5) mice. Cells were restimulated in vitro with methylated bovine serum albumin (mBSA) (10 μg/
ml, hatched columns) or concanavalin A (ConA) (5 μg/ml) or were left unstimulated (white columns). Results, expressed as fold increase in prolifera-
tion of stimulated over unstimulated cultures, represent the mean ± standard error of the mean (SEM) for each group of mice. Proliferation was sig-
nificantly increased by stimulation with mBSA or ConA in cells isolated from isotype-matched control antibody-treated mice; *p < 0.05 versus 
unstimulated cultures. This proliferative response to mBSA and ConA was significantly reduced in cells of anti-JAM-C antibody-treated mice as com-
pared to cells isolated from isotype-matched control antibody-treated mice; &p < 0.05 versus cells isolated from isotype-matched control antibody-
treated mice with similar stimulation, as assessed by analysis of variance (ANOVA). (b) Interferon-gamma (IFN-γ) production by spleen cells isolated 
from anti-JAM-C antibody-treated (n = 5) and isotype-matched control antibody-treated (n = 5) mice. Cells were restimulated in vitro with mBSA (10 
μg/ml, hatched columns) or ConA (5 μg/ml) or were left unstimulated (white columns). Results shown represent the mean ± SEM for each group of 
mice. IFN-γ production was significantly increased by stimulation with mBSA or ConA in cells isolated from isotype-matched control antibody-treated 
mice; *p < 0.05 versus unstimulated cultures. This IFN-γ response to mBSA and ConA was markedly reduced in cells of anti-JAM-C antibody-treated 
mice as compared to cells isolated from isotype-matched control antibody-treated mice; &p < 0.05 versus cells isolated from isotype-matched con-
trol antibody-treated mice with similar stimulation, as assessed by ANOVA. Serum levels of anti-mBSA total IgG (c), IgG1 ([d], left panel), and IgG2a 
([d], right panel) on days 4 and 8 after intra-articular mBSA injection. Results shown represent the mean ± SEM for anti-JAM-C antibody-treated (n 
= 6, black columns) and isotype-matched control antibody-treated (n = 5, open columns) mice. *p < 0.05 versus control mice, as assessed by 
ANOVA. Ab, antibody; A.U., arbitrary units; Ig = immunoglobulin; JAM-C, junctional adhesion molecule-C; O.D., optical density.Page 8 of 12
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[6,28]. Alternatively, the anti-JAM-C antibody may act directly
on resident synovial fibroblasts to disrupt retention of granulo-
cytes within lesions. Synovial fibroblasts are indeed potent
producers of cytokines, adhesion molecules, and chemokines
that attract and retain large numbers of leukocytes in the
inflamed synovium, thus sustaining chronic inflammation and
preventing the resumption of normal tissue homeostasis [29].
The mouse AIA model can be divided into two phases. Intra-
articular antigen injection first results in an acute inflammatory
reaction, characterized by joint swelling and leukocyte infiltra-
tion, which later proceeds to a chronic destructive arthritis with
synovial hyperplasia, and cartilage and bone erosion. In addi-
tion to an inhibitory effect of anti-JAM-C antibody treatment on
the acute inflammatory response, which is in line with previous
findings [11-13], we observed an anti-inflammatory effect in
the chronic phase of the disease, as shown by reduced inflam-
mation in the knees of mice treated with anti-JAM-C antibody
as compared to isotype-matched control antibody-treated
mice on day 8 (Figure 3b,c).
The systemic suppressive effect of anti-JAM-C on T-cell
response is an unexpected result. JAM-C is not expressed on
mouse T cells and in vitro addition of anti-JAM-C antibodies
onto spleen cell cultures did not alter cell proliferation (data
Figure 5
Treatment with anti-JAM-C antibody decreases neutrophil infiltration into the joints during antigen-induced arthritis. Infiltration of neutrophils (a), lym-
phocytes (b), and macrophages (c) into the synovium was detected by immunohistochemistry using anti-MPO, anti-CD3, and anti-MAC-2 antibod-
ies, respectively. The left panels show representative knee joint sections of control and anti-JAM-C antibody-treated mice. Original magnification × 
400 (scale bar = 25 μm). In the right panels, leukocyte infiltration per field was evaluated by semi-quantitative scoring for anti-JAM-C antibody-
treated (n = 6, black columns) and isotype-matched control antibody-treated (n = 5, open columns) mice. There was a significant decrease in syno-
vial neutrophil infiltration in anti-JAM-C antibody-treated mice as compared to isotype-matched antibody-treated controls. *p < 0.05 versus control 
mice, as assessed by analysis of variance. Ab, antibody; JAM-C, junctional adhesion molecule-C.Page 9 of 12
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the anti-JAM-C antibody may be mediated by stromal cells in
vivo. Consistent with this observation, other investigators
found no difference regarding the number of circulating lym-
phocytes between anti-JAM-C-treated and isotype control-
treated groups in a model of allergic contact dermatitis
responsive to anti-JAM-C administration [12]. We also
observed that circulating levels of lymphocytes were not sig-
nificantly decreased in naive and arthritic mice (K/BxN experi-
ments) following the administration of the anti-JAM-C or the
isotype-matched control antibody. The absolute lymphocyte
counts (mean ± standard error of the mean) were 4.5 ± 0.57
g/L (naive anti-JAM-C antibody-treated), 5.5 ± 0.41 g/L (naive
isotype-matched control antibody-treated), 6.89 ± 0.55 g/L
(arthritic anti-JAM-C antibody-treated), and 5.5 ± 0.57 g/L
(arthritic isotype-matched control antibody-treated). In addi-
Figure 6
Treatment with anti-JAM-C antibody delays onset of K/BxN serum transfer-induced arthritis. (a) Incidence of K/BxN serum transfer-induced arthritis 
is shown for anti-JAM-C antibody-treated (n = 10, black symbols) and isotype-matched control antibody-treated (n = 10, open symbols) mice. 
Results are expressed as the percentage of arthritic mice per group. Incidence of arthritis was significantly lower in anti-JAM-C antibody-treated mice 
as compared to isotype-matched antibody-treated controls on day 3. *p < 0.05 versus control mice, as assessed by chi-square test. (b) Severity of 
K/BxN serum transfer-induced arthritis. Arthritis was evaluated by clinical assessment of arthritis severity scores for anti-JAM-C antibody-treated (n = 
10, black symbols) and isotype-matched control antibody-treated (n = 10, open symbols) mice. Results shown represent the mean ± standard error 
of the mean (SEM) for each group of mice. There were no significant differences between the groups. (c) Histological assessment of arthritis. Rep-
resentative sections are shown for anti-JAM-C antibody-treated (upper panels) and isotype-matched control antibody-treated (lower panels) mice 13 
days after serum transfer. Original magnifications × 40 (left panel) (scale bar = 125 μm) and × 100 (right panel) (scale bar = 50 μm). (d) Histologi-
cal scores for synovial thickness, exudates, and edema 13 days after serum transfer. Results shown represent the mean ± SEM for anti-JAM-C anti-
body-treated (n = 10, black columns) and isotype-matched control antibody-treated (n = 10, open columns) mice. No significant differences were 
observed between the groups. Ab, antibody; JAM-C, junctional adhesion molecule-C.Page 10 of 12
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occurred when mice were treated after sensitization and
before challenge, thus indicating that JAM-C interferes with
the effector phase and not the initial antigen presentation [12].
JAM-C is expressed on synovial and other types of fibroblasts,
fibroblastic reticular cells of lymph nodes, and smooth muscle
cells [10,23]. All these cells have in common an immunoregu-
latory function, and the role of fibroblastic cells in the establish-
ment and maintenance of micro-environmental 'niches'
contributing to inflammatory diseases, including RA, has been
extensively discussed in recent reports [29-31]. Though spec-
ulative, one could imagine that anti-JAM-C treatment delivers
signals to mesenchymal cells, which in turn control the out-
come of the immune response by modulating expression of
adhesion molecules, chemokines, and cytokines [32]. Such a
hypothesis is in agreement with recent findings showing that
anti-JAM-C treatment decreases inflammation in various
mouse inflammatory models such as cerulein-induced pancre-
atitis, thioglycollate-induced peritonitis, or allergic contact der-
matitis [11-13] and that the protein may be involved in other
diseases such as obstructive nephropathy or atherosclerosis
[10,33]. An alternative explanation for the systemic pro-inflam-
matory function of JAM-C relates to its active role in favoring
diffusion of small molecules across the paravascular space.
Indeed, we have previously shown that the enrichment of the
protein at interendothelial cell-cell contacts correlates with
increased paracellular permeability and is induced by factors
inducing vascular leakage such as vascular endothelial growth
factor (VEGF) [20,34]. These results have been confirmed in
a recent study showing that antagonizing JAM-C function
results in inhibition of increased vascular permeability induced
by VEGF or histamine [35]. Thus, it is possible that treatment
of arthritic mice with the anti-JAM-C antibody results in
decreased diffusion of inflammatory mediators in the blood,
inducing a systemic immunosuppressive effect. Although this
attractive hypothesis requires more investigation, our results
uncover a link between JAM-C expression in arthritic lesions
and local and systemic anti-inflammatory effects of an antibody
directed against this protein.
There is accumulating evidence that leukocyte trafficking to
the inflamed synovium is adhesion molecule-dependent, and
the blocking adhesion molecules that mediate the accumula-
tion of leukocytes in inflammation can thus be expected to
have therapeutic potential in human RA. However, the few clin-
ical trials performed so far have not met expectations. For
instance, efazulimab, a humanized monoclonal antibody
against LFA-1, did not significantly reduce arthritis in a cohort
of patients with psoriatic arthritis [36]. Anti-ICAM-1 (intracellu-
lar adhesion molecule-1) monoclonal antibodies have been
evaluated in a phase I/II open-label study and had only limited
effects in patients with RA [37]. Finally, a randomized, pla-
cebo-controlled trial of an antisense oligodeoxynucleotide
ICAM-1 inhibitor could not demonstrate clinical efficacy
beyond that of placebo in patients with active RA [38]. Among
the possible explanations for this low efficacy are the redun-
dancy and overlapping functions of molecules that are
involved in leukocyte extravasation, due to which selective inhi-
bition of single adhesion molecules might not be sufficient to
efficiently prevent leukocyte recruitment. In the present study,
we observed that treatment with an anti-JAM-C antibody
induced anti-inflammatory effects, which seem to extend
beyond local inhibition of leukocyte adhesion. This observation
fits with the concept that the signaling activity of adhesion
molecules, in addition to their adhesive properties, may be
important for their function.
Conclusion
JAM-C is highly expressed by synovial fibroblasts in RA. Treat-
ment of mice with an anti-JAM-C antibody significantly
reduced the severity of AIA and delayed the onset of serum
transfer-induced arthritis, suggesting a role for JAM-C in the
pathogenesis of arthritis.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
GP, NB, and MA-L performed the experiments, designed the
study, and drafted the manuscript. DT-A, VC-P, CZ, and PH
performed the experiments. BAI and CG designed the study
and drafted the manuscript. All authors read and approved the
final manuscript. GP and NB contributed equally to this work.
Acknowledgements
KRN mice were kindly provided by Diane Mathis and Christophe Benoist 
through the Institut de Génétique et de Biologie Moléculaire et Cellulaire 
(Strasbourg, France). This work was supported by Swiss National Sci-
ence Foundation grant 3200-107592/1 (to CG), grant 3200-067231 
(to NB), grant 310000-112551/I (to MA-L), and grant 3100AO-
10069712 (to BAI), by the Krebsforschung Schweiz (grant to BAI), and 
by the Thorn Foundation (grant to MA-L).
References
1. Butcher EC: Leukocyte-endothelial cell recognition: three (or
more) steps to specificity and diversity.  Cell 1991,
67:1033-1036.
2. Springer TA: Traffic signals for lymphocyte recirculation and
leukocyte emigration: the multistep paradigm.  Cell 1994,
76:301-314.
3. Schenkel AR, Mamdouh Z, Chen X, Liebman RM, Muller WA:
CD99 plays a major role in the migration of monocytes
through endothelial junctions.  Nat Immunol 2002, 3:143-150.
4. Muller WA, Weigl SA, Deng X, Phillips DM: PECAM-1 is required
for transendothelial migration of leukocytes.  J Exp Med 1993,
178:449-460.
5. Johnson-Leger CA, Aurrand-Lions M, Beltraminelli N, Fasel N,
Imhof BA: Junctional adhesion molecule-2 (JAM-2) promotes
lymphocyte transendothelial migration.  Blood 2002,
100:2479-2486.
6. Chavakis T, Keiper T, Matz-Westphal R, Hersemeyer K, Sachs UJ,
Nawroth PP, Preissner KT, Santoso S: The junctional adhesion
molecule-C promotes neutrophil transendothelial migration in
vitro and in vivo.  J Biol Chem 2004, 279:55602-55608.Page 11 of 12
(page number not for citation purposes)
Arthritis Research & Therapy    Vol 9 No 4    Palmer et al.7. Ebnet K, Suzuki A, Ohno S, Vestweber D: Junctional adhesion
molecules (JAMs): more molecules with dual functions?  J Cell
Sci 2004, 117:19-29.
8. Santoso S, Sachs UJ, Kroll H, Linder M, Ruf A, Preissner KT, Cha-
vakis T: The junctional adhesion molecule 3 (JAM-3) on human
platelets is a counterreceptor for the leukocyte integrin Mac-1.
J Exp Med 2002, 196:679-691.
9. Liu Y, Nusrat A, Schnell FJ, Reaves TA, Walsh S, Pochet M, Parkos
CA: Human junction adhesion molecule regulates tight junc-
tion resealing in epithelia.  J Cell Sci 2000, 113:2363-2374.
10. Keiper T, Al-Fakhri N, Chavakis E, Athanasopoulos AN, Isermann
B, Herzog S, Saffrich R, Hersemeyer K, Bohle RM, Haendeler J, et
al.: The role of junctional adhesion molecule-C (JAM-C) in oxi-
dized LDL-mediated leukocyte recruitment.  Faseb J 2005,
19:2078-2080.
11. Aurrand-Lions M, Lamagna C, Dangerfield JP, Wang S, Herrera P,
Nourshargh S, Imhof BA: Junctional adhesion molecule-C regu-
lates the early influx of leukocytes into tissues during
inflammation.  J Immunol 2005, 174:6406-6415.
12. Ludwig RJ, Zollner TM, Santoso S, Hardt K, Gille J, Baatz H,
Johann PS, Pfeffer J, Radeke HH, Schon MP, et al.: Junctional
adhesion molecules (JAM)-B and -C contribute to leukocyte
extravasation to the skin and mediate cutaneous
inflammation.  J Invest Dermatol 2005, 125:969-976.
13. Vonlaufen A, Aurrand-Lions M, Pastor CM, Lamagna C, Hadengue
A, Imhof BA, Frossard JL: The role of junctional adhesion mole-
cule C (JAM-C) in acute pancreatitis.  J Pathol 2006,
209:540-548.
14. Kouskoff V, Korganow AS, Duchatelle V, Degott C, Benoist C,
Mathis D: Organ-specific disease provoked by systemic
autoimmunity.  Cell 1996, 87:811-822.
15. Lamagna C, Meda P, Mandicourt G, Brown J, Gilbert RJ, Jones EY,
Kiefer F, Ruga P, Imhof BA, Aurrand-Lions M: Dual interaction of
JAM-C with JAM-B and alpha(M)beta2 integrin: function in
junctional complexes and leukocyte adhesion.  Mol Biol Cell
2005, 16:4992-5003.
16. Busso N, So A, Chobaz-Péclat V, Morard C, Martinez-Soria E, Tal-
abot-Ayer D, Gabay C: Leptin signaling deficiency impairs
humoral and cellular immune responses and attenuates
experimental arthritis.  J Immunol 2002, 168:875-882.
17. Lamagna C, Hodivala-Dilke KM, Imhof BA, Aurrand-Lions M: Anti-
body against junctional adhesion molecule-C inhibits angio-
genesis and tumor growth.  Cancer Res 2005, 65:5703-5710.
18. Ody C, Jungblut-Ruault S, Cossali D, Barnet M, Aurrand-Lions M,
Imhof BA, Matthes T: Junctional adhesion molecule C (JAM-C)
distinguishes CD27+ germinal center B lymphocytes from
non-germinal center cells and constitutes a new diagnostic
tool for B-cell malignancies.  Leukemia 2007, 21:1285-1293.
19. Palmer G, Burger D, Mezin F, Magne D, Gabay C, Dayer JM,
Guerne PA: The active metabolite of leflunomide, A77
increases the production of IL-1 receptor antagonist in human
synovial fibroblasts and articular chondrocytes.  Arthritis Res
Ther 2007, 6:R181-189.
20. Magne D, Palmer G, Barton JL, Mezin F, Talabot-Ayer D, Bas S,
Duffy T, Noger M, Guerne PA, Nicklin MJ, et al.: The new IL-1 fam-
ily member IL-1F8 stimulates production of inflammatory
mediators by synovial fibroblasts and articular chondrocytes.
Arthritis Res Ther 2006, 8:R80.
21. Sipe JD, Gonnerman WA, Loose LD, Knapschaefer G, Xie WJ,
Franzblau C: Direct binding enzyme-linked immunosorbent
assay (ELISA) for serum amyloid A (SAA).  J Immunol Methods
1989, 125:125-135.
22. Zen K, Babbin BA, Liu Y, Whelan JB, Nusrat A, Parkos CA: JAM-
C is a component of desmosomes and a ligand for CD11b/
CD18-mediated neutrophil transepithelial migration.  Mol Biol
Cell 2004, 15:3926-3937.
23. Morris AP, Tawil A, Berkova Z, Wible L, Smith CW, Cunningham
SA: Junctional adhesion molecules (JAMs) are differentially
expressed in fibroblasts and co-localize with ZO-1 to adher-
ens-like junctions.  Cell Commun Adhes 2006, 13:233-247.
24. Tarrant TK, Patel DD: Chemokines and leukocyte trafficking in
rheumatoid arthritis.  Pathophysiology 2006, 13:1-14.
25. Issekutz AC, Issekutz TB: Monocyte migration to arthritis in the
rat utilizes both CD11/CD18 and very late activation antigen 4
integrin mechanisms.  J Exp Med 1995, 181:1197-1203.
26. Issekutz TB, Miyasaka M, Issekutz AC: Rat blood neutrophils
express very late antigen 4 and it mediates migration to
arthritic joint and dermal inflammation.  J Exp Med 1996,
183:2175-2184.
27. Taylor PC, Chu CQ, Plater-Zyberk C, Maini RN: Transfer of type
II collagen-induced arthritis from DBA/1 to severe combined
immunodeficiency mice can be prevented by blockade of Mac-
1.  Immunology 1996, 88:315-321.
28. Cunningham SA, Rodriguez JM, Arrate MP, Tran TM, Brock TA:
JAM2 interacts with alpha4beta1. Facilitation by JAM3.  J Biol
Chem 2002, 277:27589-27592.
29. Burman A, Haworth O, Bradfield P, Parsonage G, Filer A, Thomas
AM, Amft N, Salmon M, Buckley CD: The role of leukocyte-stro-
mal interactions in chronic inflammatory joint disease.  Joint
Bone Spine 2005, 72:10-16.
30. Parsonage G, Filer AD, Haworth O, Nash GB, Rainger GE, Salmon
M, Buckley CD: A stromal address code defined by fibroblasts.
Trends Immunol 2005, 26:150-156.
31. Mor A, Abramson SB, Pillinger MH: The fibroblast-like synovial
cell in rheumatoid arthritis: a key player in inflammation and
joint destruction.  Clin Immunol 2005, 115:118-128.
32. Katakai T, Hara T, Sugai M, Gonda H, Shimizu A: Lymph node
fibroblastic reticular cells construct the stromal reticulum via
contact with lymphocytes.  J Exp Med 2004, 200:783-795.
33. Lange-Sperandio B, Schimpgen K, Rodenbeck B, Chavakis T,
Bierhaus A, Nawroth P, Thornhill B, Schaefer F, Chevalier RL: Dis-
tinct roles of Mac-1 and its counter-receptors in neonatal
obstructive nephropathy.  Kidney Int 2006, 69:81-88.
34. Aurrand-Lions M, Johnson-Leger C, Wong C, Du Pasquier L, Imhof
BA: Heterogeneity of endothelial junctions is reflected by dif-
ferential expression and specific subcellular localization of the
three JAM family members.  Blood 2001, 98:3699-3707.
35. Orlova VV, Economopoulou M, Lupu F, Santoso S, Chavakis T:
Junctional adhesion molecule-C regulates vascular endothe-
lial permeability by modulating VE-cadherin-mediated cell-cell
contacts.  J Exp Med 2006, 203:2703-2714.
36. Gladman DD: Psoriatic arthritis.  Dermatol Ther 2004,
17:350-363.
37. Kavanaugh AF, Davis LS, Jain RI, Nichols LA, Norris SH, Lipsky PE:
A phase I/II open label study of the safety and efficacy of an
anti-ICAM-1 (intercellular adhesion molecule-1; CD54) mono-
clonal antibody in early rheumatoid arthritis.  J Rheumatol
1996, 23:1338-1344.
38. Maksymowych WP, Blackburn WD Jr, Tami JA, Shanahan WR Jr:
A randomized, placebo controlled trial of an antisense
oligodeoxynucleotide to intercellular adhesion molecule-1 in
the treatment of severe rheumatoid arthritis.  J Rheumatol
2002, 29:447-453.Page 12 of 12
(page number not for citation purposes)
